Cover Image

Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by mendelian randomization

Objective In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. Methods A genome-wide association study meta-analysis was performed of circulating sclerostin levels in 33,961 European...

Full description

Saved in:
Bibliographic Details
Main Authors: Zheng, Jie (Author) , Wheeler, Eleanor (Author) , Pietzner, Maik (Author) , Andlauer, Till F. M. (Author) , Yau, Michelle S. (Author) , Hartley, April E. (Author) , Brumpton, Ben Michael (Author) , Rasheed, Humaira (Author) , Kemp, John P. (Author) , Frysz, Monika (Author) , Robinson, Jamie (Author) , Reppe, Sjur (Author) , Prijatelj, Vid (Author) , Gautvik, Kaare M. (Author) , Falk, Louise (Author) , März, Winfried (Author) , Gergei, Ingrid (Author) , Peyser, Patricia A. (Author) , Kavousi, Maryam (Author) , Vries, Paul S. de (Author) , Miller, Clint L. (Author) , Bos, Maxime (Author) , van der Laan, Sander W. (Author) , Malhotra, Rajeev (Author) , Herrmann, Markus (Author) , Scharnagl, Hubert (Author) , Kleber, Marcus E. (Author) , Dedoussis, George (Author) , Zeggini, Eleftheria (Author) , Nethander, Maria (Author) , Ohlsson, Claes (Author) , Lorentzon, Mattias (Author) , Wareham, Nick (Author) , Langenberg, Claudia (Author) , Holmes, Michael V. (Author) , Davey Smith, George (Author) , Tobias, Jonathan H. (Author)
Format: Article (Journal)
Language:English
Published: October 2023
In: Arthritis & rheumatology
Year: 2023, Volume: 75, Issue: 10, Pages: 1781-1792
ISSN:2326-5205
DOI:10.1002/art.42538
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/art.42538
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.42538
Get full text
Author Notes:Jie Zheng, Eleanor Wheeler, Maik Pietzner, Till FM Andlauer, Michelle S Yau, April E Hartley, Ben Michael Brumpton, Humaira Rasheed, John P Kemp, Monika Frysz, Jamie Robinson, Sjur Reppe, Vid Prijatelj, Kaare M Gautvik, Louise Falk, Winfried Maerz, Ingrid Gergei, Patricia A Peyser, Maryam Kavousi, Paul S de Vries, Clint L Miller, Maxime Bos, Sander W van der Laan, Rajeev Malhotra, Markus Herrmann, Hubert Scharnagl, Marcus Kleber, George Dedoussis, Eleftheria Zeggini, Maria Nethander, Claes Ohlsson, Mattias Lorentzon, Nick Wareham, Claudia Langenberg, Michael V Holmes, George Davey Smith, and Jonathan H Tobias
Description
Summary:Objective In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. Methods A genome-wide association study meta-analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15 atherosclerosis-related diseases and risk factors. Results We found that 18 conditionally independent variants were associated with circulating sclerostin. Of these, 1 cis signal in SOST and 3 trans signals in B4GALNT3, RIN3, and SERPINA1 regions showed directionally opposite signals for sclerostin levels and estimated bone mineral density. Variants with these 4 regions were selected as genetic instruments. MR using 5 correlated cis-SNPs suggested that lower sclerostin increased the risk of type 2 diabetes mellitus (DM) (odds ratio [OR] 1.32 [95% confidence interval (95% CI) 1.03-1.69]) and myocardial infarction (MI) (OR 1.35 [95% CI 1.01-1.79]); sclerostin lowering was also suggested to increase the extent of coronary artery calcification (CAC) (β = 0.24 [95% CI 0.02-0.45]). MR using both cis and trans instruments suggested that lower sclerostin increased hypertension risk (OR 1.09 [95% CI 1.04-1.15]), but otherwise had attenuated effects. Conclusion This study provides genetic evidence to suggest that lower levels of sclerostin may increase the risk of hypertension, type 2 DM, MI, and the extent of CAC. Taken together, these findings underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors.
Item Description:Online veröffentlicht: 25. April 2023
Gesehen am 07.02.2024
Physical Description:Online Resource
ISSN:2326-5205
DOI:10.1002/art.42538

Similar Items